MDXG
Price
$7.70
Change
+$0.09 (+1.18%)
Updated
Mar 28, 6:59 PM EST
32 days until earnings call
PTGX
Price
$28.93
Change
+$0.45 (+1.58%)
Updated
Mar 28, 6:59 PM EST
33 days until earnings call
Ad is loading...

MDXG vs PTGX ᐉ Comparison: Which is Better to Invest?

Header iconMDXG vs PTGX Comparison
Open Charts MDXG vs PTGXBanner chart's image
MiMedx Group
Price$7.70
Change+$0.09 (+1.18%)
Volume$647.01K
CapitalizationN/A
Protagonist Therapeutics
Price$28.93
Change+$0.45 (+1.58%)
Volume$359.57K
CapitalizationN/A
View a ticker or compare two or three
MDXG vs PTGX Comparison Chart

Loading...

MDXGDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PTGXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
MDXG vs. PTGX commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDXG is a Sell and PTGX is a StrongBuy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (MDXG: $7.68 vs. PTGX: $28.93)
Brand notoriety: MDXG and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDXG: 91% vs. PTGX: 60%
Market capitalization -- MDXG: $1.13B vs. PTGX: $1.69B
MDXG [@Biotechnology] is valued at $1.13B. PTGX’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDXG’s FA Score shows that 1 FA rating(s) are green whilePTGX’s FA Score has 0 green FA rating(s).

  • MDXG’s FA Score: 1 green, 4 red.
  • PTGX’s FA Score: 0 green, 5 red.
According to our system of comparison, MDXG is a better buy in the long-term than PTGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDXG’s TA Score shows that 3 TA indicator(s) are bullish while PTGX’s TA Score has 5 bullish TA indicator(s).

  • MDXG’s TA Score: 3 bullish, 6 bearish.
  • PTGX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than MDXG.

Price Growth

MDXG (@Biotechnology) experienced а -5.88% price change this week, while PTGX (@Biotechnology) price change was +2.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

MDXG is expected to report earnings on Apr 30, 2024.

PTGX is expected to report earnings on May 01, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDXG with price predictions.
OPEN
A.I.dvisor published
a Summary for PTGX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
PTGX($1.69B) has a higher market cap than MDXG($1.13B). PTGX YTD gains are higher at: 26.167 vs. MDXG (-12.429). MDXG has higher annual earnings (EBITDA): 40.5M vs. PTGX (-90.34M). PTGX has more cash in the bank: 342M vs. MDXG (82M). PTGX has less debt than MDXG: PTGX (1.14M) vs MDXG (48.1M). MDXG has higher revenues than PTGX: MDXG (321M) vs PTGX (60M).
MDXGPTGXMDXG / PTGX
Capitalization1.13B1.69B67%
EBITDA40.5M-90.34M-45%
Gain YTD-12.42926.167-47%
P/E Ratio17.86N/A-
Revenue321M60M535%
Total Cash82M342M24%
Total Debt48.1M1.14M4,216%
FUNDAMENTALS RATINGS
MDXG vs PTGX: Fundamental Ratings
MDXG
PTGX
OUTLOOK RATING
1..100
6065
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
6356
SMR RATING
1..100
1496
PRICE GROWTH RATING
1..100
4740
P/E GROWTH RATING
1..100
68100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (52) in the Biotechnology industry is in the same range as MDXG (70). This means that PTGX’s stock grew similarly to MDXG’s over the last 12 months.

PTGX's Profit vs Risk Rating (56) in the Biotechnology industry is in the same range as MDXG (63). This means that PTGX’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for PTGX (96). This means that MDXG’s stock grew significantly faster than PTGX’s over the last 12 months.

PTGX's Price Growth Rating (40) in the Biotechnology industry is in the same range as MDXG (47). This means that PTGX’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (68) in the Biotechnology industry is in the same range as PTGX (100). This means that MDXG’s stock grew similarly to PTGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDXGPTGX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
MDXGDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PTGXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHTCX43.140.05
+0.12%
Columbia Seligman Global Tech C
VNVYX25.840.02
+0.08%
Natixis Vaughan Nelson Mid Cap Y
RIIEX37.53-0.04
-0.11%
American Funds Intl Gr and Inc R2E
SGNFX38.58-0.05
-0.13%
Sparrow Growth No-Load
RMQCX469.23-1.66
-0.35%
Rydex Monthly Rbl NASDAQ-100® 2x Strt C

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+0.92%
AXON - MDXG
47%
Loosely correlated
-0.98%
INVA - MDXG
45%
Loosely correlated
-0.39%
PRTA - MDXG
43%
Loosely correlated
-1.55%
VCYT - MDXG
42%
Loosely correlated
+1.84%
GERN - MDXG
40%
Loosely correlated
-0.60%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with CARA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then CARA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+1.58%
CARA - PTGX
40%
Loosely correlated
+5.75%
ARDX - PTGX
40%
Loosely correlated
-1.48%
OCUL - PTGX
39%
Loosely correlated
-2.26%
TNYA - PTGX
38%
Loosely correlated
+0.97%
GERN - PTGX
38%
Loosely correlated
-0.60%
More